3937-49-3

Usage

Uses

Used in Flavor and Fragrance Industry:
4α-Methylcyclohexane-1β-methanol is utilized as a fragrance and flavoring agent in various consumer products due to its mild, minty scent. It adds a refreshing quality to products, making it a popular choice for items such as toothpaste, mouthwash, and chewing gum.
Used in Pharmaceutical Applications:
4α-Methylcyclohexane-1β-methanol has been studied for its potential therapeutic effects, which include analgesic and anti-inflammatory properties. This suggests that 4α-Methylcyclohexane-1β-methanol could be used in the development of medications aimed at relieving pain and reducing inflammation.
Used in Cosmetics and Personal Care Products:
Given its pleasant odor and potential therapeutic benefits, 4α-Methylcyclohexane-1β-methanol may also find use in the cosmetics and personal care industry, where it could be incorporated into products to provide a refreshing scent and possibly contribute to soothing skin or other applications.
It is important to consider the safety and regulatory guidelines when using 4α-Methylcyclohexane-1β-methanol in any of these applications to ensure that exposure levels are controlled and do not lead to adverse effects on health.

Upstream product

• 41692-50-6 trans-4-methyl-1-(ethoxycarbonyl)cyclohexane 
• 934-67-8 trans-4-methylcyclohexanecarboxylic acid 
• 39155-38-9 (4-methylcyclohex-3-en-1-yl)methanol 
• 55930-23-9 trans-4-methylcyclohexanecarbonyl chloride 
• 2808-80-2 4-methyl-1-methylidenecyclohexane 
• 99-94-5 p-Toluic acid 
• 589-91-3 p-methylcyclohexanol 
• 78-79-5 isoprene 
• 20292-15-3 4-methyl-cyclohex-3-enecarboxylic acid ethyl ester 
• 94-60-0 dimethyl 1,4-cyclohexane dicarboxylate 
• 3236-48-4 trans-1,4-Cyclohexanedimethanol 
• 170811-08-2 trans-4-(hydroxymethyl)cyclohexylmethyl 4-methylbenzenesulfonate 
• 6493-79-4 methyl 4-methyl-3-cyclohexene-1-carboxylate 

Downstream Products

• 1658500-48-1 tert-butyl (2,6-dichloro-3-(((trans-4-methylcyclohexyl)methyl)amino)pyridin-4-yl)carbamate 
• 1658500-49-2 2,6-dichloro-N³-((trans-4-methylcyclohexyl)methyl)pyridine-3,4-diamine 
• 1616434-24-2 4,6-dichloro-3-(((trans)-4-methylcyclohexyl)methyl)-3H-imidazo[4,5-c]pyridine 
• 1616434-25-3 2-bromo-4,6-dichloro-3-(((trans)-4-methylcyclohexyl)methyl)-3H-imidazo[4,5-c]pyridine 
• 1616434-26-4 4,6-dichloro-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridine 
• 1616434-27-5 6-chloro-4-(5-chloropyridin-3-yl)-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridine 
• 1616434-28-6 4-(5-chloropyridin-3-yl)-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridine-6-carbonitrile 
• 1658500-50-5 4-(5-chloropyridin-3-yl)-N'-hydroxy-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridine-6-carboximidamide 
• 1616428-74-0 5-{4-(5-chloropyridin-3-yl)-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridin-6-yl}-1,3,4-oxadiazol-2(3H)-one 
• 1616431-67-4 methyl 4-(5-chloropyridin-3-yl)-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridine-6-carboxylate 
• 1658500-51-6 4-(5-chloropyridin-3-yl)-3-[(trans-4-methylcyclohexyl)methyl]-2-[(3R)-3-phenylmorpholin-4-yl]-3H-imidazo[4,5-c]pyridine-6-carbohydrazide 
• 148258-68-8 (Z)-6-(trans-4-Methylcyclohexyl)-5-hexen-1-ol 

Relevant academic research and scientific papers

Discovery of MK-4688: An Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction

Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward this goal. Adding to recent success in this area, we describe herein our efforts to optimize a novel purine carboxylic acid-derived inhibitor of the HDM2-p53 PPI into a series of low-projected dose inhibitors with overall favorable pharmacokinetic and physical properties. Ultimately, a strategy focused on leveraging known binding hot spots coupled with biostructural information to guide the design of conformationally constrained analogs and a focus on efficiency metrics led to the discovery of MK-4688 (compound 56), a highly potent, selective, and low-molecular-weight inhibitor suitable for clinical investigation.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a formula I or a stereoisomer thereof in preparation of medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a f

Hydrogenation of alkenes via cooperative hydrogen atom transfer

Radical hydrogenation via hydrogen atom transfer (HAT) to alkenes is an increasingly important transformation for the formation of thermodynamic alkane isomers. Current single-catalyst methods require stoichiometric oxidant in addition to hydride (H-) source to function. Here we report a new approach to radical hydrogenation: cooperative hydrogen atom transfer (cHAT), where each hydrogen atom donated to the alkene arrives from a different catalyst. Further, these hydrogen atom (H?) equivalents are generated from complementary hydrogen atom precursors, with each alkane requiring one hydride (H-) and one proton (H+) equivalent and no added oxidants. Preliminary mechanistic study supports this reaction manifold and shows the intersection of metal-catalyzed HAT and thiol radical trapping HAT catalytic cycles to be essential for effective catalysis. Together, this unique catalyst system allows us to reduce a variety of unactivated alkene substrates to their respective alkanes in high yields and diastereoselectivities and introduces a new approach to radical hydrogenation.

SPIROCYCLIC INDANE ANALOGUES AS IL-17 MODULATORS

A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory

FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS

A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

SPIROCYCLIC INDOLINES AS IL-17 MODULATORS

A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

Simple, chemoselective hydrogenation with thermodynamic stereocontrol

Few methods permit the hydrogenation of alkenes to a thermodynamically favored configuration when steric effects dictate the alternative trajectory of hydrogen delivery. Dissolving metal reduction achieves this control, but with extremely low functional group tolerance. Here we demonstrate a catalytic hydrogenation of alkenes that affords the thermodynamic alkane products with remarkably broad functional group compatibility and rapid reaction rates at standard temperature and pressure.

Bis(phosphine)cobalt dialkyl complexes for directed catalytic alkene hydrogenation

Planar, low-spin cobalt(II) dialkyl complexes bearing bidentate phosphine ligands, (P - P)Co-(CH2SiMe3)2, are active for the hydrogenation of geminal and 1,2-disubstituted alkenes. Hydrogenation of more hindered internal and endocyclic trisubstituted alkenes was achieved through hydroxyl group activation, an approach that also enables directed hydrogenations to yield contrasteric isomers of cyclic alkanes.

SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS

The present invention provides substituted pyrrolopyrimidines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compos